Biopharma firm Avalyn Pharma Inc. has filed for a U.S. initial public offering, positioning itself as a developer of inhaled therapies for respiratory disorders. The move follows the company’s recent partnership with Novo Holdings, which has injected capital to accelerate clinical programs. Investors will now assess how the IPO could fund next‑phase trials and broaden market reach.

By going public, Avalyn seeks to raise capital that will support its pipeline of inhalation products targeting conditions such as asthma and chronic obstructive pulmonary disease. The filing signals confidence in the growing inhaled‑drug market, which analysts project to expand at a compound annual growth rate of double‑digits over the next decade. Market participants will watch the valuation to gauge investor appetite and to secure strategic partnerships.

Regulatory approval will be the next hurdle, as the company must demonstrate safety and efficacy in large‑scale trials before listing. Should the IPO succeed, Avalyn could secure a valuation that positions it among the top U.S. biotech newcomers. The filing also reflects broader investor enthusiasm for niche respiratory therapeutics, potentially reshaping capital flows in the sector.